HRP20161030T1 - Protutijelu slični vezivni proteini s dvostrukom promjenjivom regijom koji imaju prijelaznu orjentaciju vezivne regije - Google Patents

Protutijelu slični vezivni proteini s dvostrukom promjenjivom regijom koji imaju prijelaznu orjentaciju vezivne regije Download PDF

Info

Publication number
HRP20161030T1
HRP20161030T1 HRP20161030TT HRP20161030T HRP20161030T1 HR P20161030 T1 HRP20161030 T1 HR P20161030T1 HR P20161030T T HRP20161030T T HR P20161030TT HR P20161030 T HRP20161030 T HR P20161030T HR P20161030 T1 HRP20161030 T1 HR P20161030T1
Authority
HR
Croatia
Prior art keywords
amino acid
acid residues
immunoglobulin
length
heavy chain
Prior art date
Application number
HRP20161030TT
Other languages
English (en)
Inventor
Nicolas Baurin
Christian Beil
Carsten Corvey
Christian Lange
Danxi Li
Vincent Mikol
Anke Steinmetz
Ercole Rao
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46927552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161030(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20161030T1 publication Critical patent/HRP20161030T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Claims (16)

1. Protutijelu sličan vezivni protein koji sadrži četiri polipeptidna lanca koji tvore četiri mjesta vezanja antigena, pri čemu dva polipeptidna lanca imaju strukturu predstavljenu s formulom: [image] i dva polipeptidna lanca imaju strukturu predstavljenu s formulom: [image] pri čemu: VL1 je varijabilna domena prvog lakog imunoglobulinskog lanca; VL2 je varijabilna domena drugog lakog imunoglobulinskog lanca; VH1 je varijabilna domena prvog teškog imunoglobulinskog lanca; VH2 je varijabilna domena drugog teškog imunoglobulinskog lanca; CL je konstantna domena lakog imunoglobulinskog lanca; CH1 je imunoglobulinska CH1 konstantna domena teškog lanca; Fc je imunoglobulinska zglobna regija i CH2, CH3 imunoglobulinska konstantna domena teških lanaca; i L1, L2, L3, i L4 su amino kiselinske poveznice; pri čemu: L1 je duljine 3 do 12 ostataka amino kiseline; L2 je duljine 3 do 14 ostataka amino kiseline; L3 je duljine 1 do 8 ostataka amino kiseline; i L4 je duljine 1 do 3 ostataka amino kiseline; i pri čemu polipeptidi s formulom I i polipeptidi s formulom II tvore prijelazni par laki lanac-teški lanac.
2. Protutijelu sličan vezivni protein koji sadrži dva polipeptidna lanca koji tvore dva mjesta vezivanja antigena, pri čemu prvi polipeptidni lanac ima strukturu predstavljenu s formulom: [image] i drugi polipeptidni lanac ima strukturu predstavljenu s formulom: [image] pri čemu: VL1 je varijabilna domena prvog lakog imunoglobulinskog lanca; VL2 je varijabilna domena drugog lakog imunoglobulinskog lanca; VH1 je varijabilna domena prvog teškog imunoglobulinskog lanca; VH2 je varijabilna domena drugog teškog imunoglobulinskog lanca; CL je konstantna domena lakog imunoglobulinskog lanca; CH1 je imunoglobulinska CH1 konstantna domena teškog lanca; i L1, L2, L3, i L4 su amino kiselinske poveznice; pri čemu: L1 je duljine 3 do 12 ostataka amino kiseline; L2 je duljine 3 do 14 ostataka amino kiseline; L3 je duljine 1 do 8 ostataka amino kiseline; i L4 je duljine 1 do 3 ostatka amino kiseline; i pri čemu prvi i drugi polipeptidi tvore prijelazni par laki lanac-teški lanac.
3. Protutijelu sličan vezivni protein prema bilo kojem zahtjevu 1 ili 2, pri čemu: L1 je duljine 5 do 10 ostataka amino kiseline; L2 je duljine 5 do 8 ostataka amino kiseline; L3 je duljine 1 do 5 ostataka amino kiseline; i L4 je duljine 1 do 2 ostatka amino kiseline.
4. Protutijelu sličan vezivni protein prema bilo kojem zahtjevu 1 ili 2, pri čemu: L1 je duljine 7 ostataka amino kiseline; L2 je duljine 5 ostataka amino kiseline; L3 je duljine 1 ostatak amino kiseline; i L4 je duljine 2 ostatka amino kiseline.
5. Protutijelu sličan vezivni protein koji sadrži četiri polipeptidna lanca koji tvore četiri mjesta vezanja antigena, pri čemu dva polipeptidna lanca imaju strukturu predstavljenu s formulom: [image] i dva polipeptidna lanca imaju strukturu predstavljenu s formulom: [image] pri čemu: VL1 je varijabilna domena prvog lakog imunoglobulinskog lanca; VL2 je varijabilna domena drugog lakog imunoglobulinskog lanca; VH1 je varijabilna domena prvog teškog imunoglobulinskog lanca; VH2 je varijabilna domena drugog teškog imunoglobulinskog lanca; CL je konstantna domena lakog imunoglobulinskog lanca; CH1 je imunoglobulinska CH1 konstantna domena teškog lanca; Fc je imunoglobulinska zglobna regija i CH2, CH3 imunoglobulinska konstantna domena teških lanaca; i L1, L2, L3, i L4 su amino kiselinske poveznice; pri čemu: L1 je duljine 1 do 3 ostatka amino kiseline; L2 je duljine 1 do 4 ostatka amino kiseline; L3 je duljine 2 do 15 ostataka amino kiseline; i L4 je duljine 2 do 15 ostataka amino kiseline; i pri čemu polipeptidi s formulom I i polipeptidi s formulom II tvore prijelazni par laki lanac-teški lanac.
6. Protutijelu sličan vezivni protein koji sadrži dva polipeptidna lanca koji tvore dva mjesta vezivanja antigena, pri čemu prvi polipeptidni lanac ima strukturu predstavljenu s formulom: [image] i drugi polipeptidni lanac ima strukturu predstavljenu s formulom: [image] pri čemu: VL1 je varijabilna domena prvog lakog imunoglobulinskog lanca; VL2 je varijabilna domena drugog lakog imunoglobulinskog lanca; VH1 je varijabilna domena prvog teškog imunoglobulinskog lanca; VH2 je varijabilna domena drugog teškog imunoglobulinskog lanca; CL je konstantna domena lakog imunoglobulinskog lanca; CH1 je imunoglobulinska CH1 konstantna domena teškog lanca; i L1, L2, L3, i L4 su amino kiselinske poveznice; pri čemu: L1 je duljine 1 do 3 ostatka amino kiseline; L2 je duljine 1 do 4 ostatka amino kiseline; L3 je duljine 2 do 15 ostataka amino kiseline; i L4 je duljine 2 do 15 ostataka amino kiseline; i pri čemu prvi i drugi polipeptidi tvore prijelazni par laki lanac-teški lanac.
7. Protutijelu sličan vezivni protein prema bilo kojem zahtjevu 5 ili 6, naznačen time da: L1 je duljine 1 do 2 ostatka amino kiseline; L2 je duljine 1 do 2 ostatka amino kiseline; L3 je duljine 4 do 12 ostataka amino kiseline; i L4 je duljine 2 do 12 ostataka amino kiseline.
8. Protutijelu sličan vezivni protein prema bilo kojem zahtjevu 5 ili 6, naznačen time da: L1 je duljine 1 ostatak amino kiseline; L2 je duljine 2 ostatka amino kiseline; L3 je duljine 7 ostataka amino kiseline; i L4 je duljine 5 ostataka amino kiseline.
9. Protutijelu sličan vezivni protein prema bilo kojem od zahtjeva 1, 2, 5 ili 6, naznačen time da vezivni peptid može specifično vezati jedan ili više antigenskih ciljeva, pri čemu, poželjno, jedan ili više antigenskih ciljeva se bira iz skupine koju čine B7.1, B7.2, BAFF, BlyS, C3, C5, CCL11 (eotaksin), CCL15 (MIP-ld), CCL17 (TARC), CCL19 (MIP-3b), CCL2 (MCP-1), CCL20 (MIP-3a), CCL21 (MIP-2), SLC, CCL24 (MPIF-2/eotaxin-2), CCL25 (TECK), CCL26 (eotaxin-3), CCL3 (MIP-la), CCL4 (MIP-lb), CCL5 (RANTES), CCL7 (MCP-3), CCL8 (mcp-2), CD3, CD19, CD20, CD24, CD40, CD40L, CD80, CD86, CDH1 (E-kadherin), Kitinaza, CSF1 (M-CSF), CSF2 (GM-CSF), CSF3 (GCSF), CTLA4, CX3CL1 (SCYD1), CXCL12 (SDF1), CXCL13, EGFR, FCER1A, FCER2, HER2, IGF1R, IL-1, IL-12, IL13, IL15, IL17, IL18, IL1A, IL1B, IL1F10, IL1β, IL2, IL4, IL6, IL7, IL8, IL9, IL12/23, IL22, IL23, IL25, IL27, IL35, ITGB4 (b 4 integrin), LEP (leptin), MHC razred II, TLR2, TLR4, TLR5, TNF, TNFα, TNFSF4 (OX40 ligand), TNFSF5 (CD40 ligand), Toll-slični receptori, TREM1, TSLP, TWEAK, XCR1 (GPR5/CCXCR1), DNGR-1(CLEC91), i HMGB1.
10. Protutijelu sličan vezivni protein prema bilo kojem od zahtjeva 1, 2, 5 ili 6, naznačen time da vezivni peptid je bispecifičan i može vezati dva različita antigenska cilja, pri čemu, poželjno, dva različita antigenska cilja se biraju iz skupine koju čine IL4 i IL13, IGF1R i HER2, IGF1R i EGFR, EGFR i HER2, BK i IL13, PDL-1 i CTLA-4, CTLA4 i MHC razred II, IL-12 i IL-18, IL-1α i IL-1β, TNFα i IL12/23, TNFα i IL-12p40, TNFα i IL1β, TNFα i IL-23, i IL17 i IL23.
11. Protutijelu sličan vezivni protein prema bilo kojem od zahtjeva 1, 2, 5 ili 6, naznačen time da vezivni peptid može inhibirati funkciju jednog ili više antigenskih ciljeva.
12. Protutijelu sličan vezivni protein prema bilo kojem od zahtjeva 1, 2, 5 ili 6, naznačen time da barem jedna od poveznica odabrana iz skupine koju čine L1, L2, L3, i L4 sadrži barem jedan cisteinski ostatak.
13. Izolirana molekula nukleinske kiseline naznačena time da sadrži nukleotidnu sekvencu koja kodira protutijelu sličan vezivni peptid prema bilo kojem od zahtjeva 1, 2, 5 ili 6.
14. Ekspresijski vektor naznačen time da sadrži molekulu nukleinske kiseline prema zahtjevu13.
15. Izolirana stanica domaćin naznačena time da sadrži molekulu nukleinske kiseline prema zahtjevu 13 ili ekspresijski vektor prema zahtjevu 14, pri čemu, poželjno, stanica domaćin je stanica sisavca ili stanica insekta.
16. Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljiv nosač i terapeutski učinkovitu količinu protutijelu sličnog vezivnog peptida prema bilo kojem od zahtjeva 1, 2, 5 ili 6.
HRP20161030TT 2011-03-28 2016-08-17 Protutijelu slični vezivni proteini s dvostrukom promjenjivom regijom koji imaju prijelaznu orjentaciju vezivne regije HRP20161030T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161468276P 2011-03-28 2011-03-28
FR1160311 2011-11-14
PCT/US2012/030948 WO2012135345A1 (en) 2011-03-28 2012-03-28 Dual variable region antibody-like binding proteins having cross-over binding region orientation
EP12716818.5A EP2691416B1 (en) 2011-03-28 2012-03-28 Dual variable region antibody-like binding proteins having cross-over binding region orientation

Publications (1)

Publication Number Publication Date
HRP20161030T1 true HRP20161030T1 (hr) 2016-10-21

Family

ID=46927552

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161030TT HRP20161030T1 (hr) 2011-03-28 2016-08-17 Protutijelu slični vezivni proteini s dvostrukom promjenjivom regijom koji imaju prijelaznu orjentaciju vezivne regije

Country Status (31)

Country Link
US (7) US20120251541A1 (hr)
EP (4) EP3805262A1 (hr)
JP (6) JP6023172B2 (hr)
KR (3) KR101974901B1 (hr)
CN (3) CN103562221B (hr)
AR (4) AR085726A1 (hr)
AU (1) AU2012236603B2 (hr)
BR (3) BR112013024758B1 (hr)
CA (1) CA2831603C (hr)
CL (1) CL2018001827A1 (hr)
CO (1) CO6781527A2 (hr)
CY (1) CY1118807T1 (hr)
DK (2) DK3199547T3 (hr)
ES (1) ES2588306T3 (hr)
HR (1) HRP20161030T1 (hr)
HU (1) HUE028230T2 (hr)
IL (4) IL299392A (hr)
LT (1) LT2691416T (hr)
MA (1) MA35051B1 (hr)
MX (1) MX338907B (hr)
MY (1) MY164906A (hr)
PL (2) PL3199547T3 (hr)
PT (1) PT2691416T (hr)
RS (2) RS61399B1 (hr)
RU (1) RU2695880C2 (hr)
SG (1) SG193916A1 (hr)
SI (2) SI3199547T1 (hr)
TW (5) TWI671315B (hr)
UY (1) UY33983A (hr)
WO (1) WO2012135345A1 (hr)
ZA (1) ZA201307017B (hr)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
EP2686014A1 (en) 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CN103687872A (zh) 2011-04-22 2014-03-26 新兴产品开发西雅图有限公司 前列腺特异性膜抗原结合蛋白和相关组合物以及方法
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10167335B2 (en) 2012-02-13 2019-01-01 Agency For Science, Technology And Research IL-1β neutralizing human monoclonal antibodies
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
LT3366705T (lt) 2012-09-12 2023-07-25 Genzyme Corporation Polipeptidai, turintys fc domeną, kurių glikozilinimas pakeistas ir susilpninta efektorinė funkcija
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
MX2015008446A (es) * 2012-12-28 2016-10-26 Abbvie Inc Composiciones de proteinas de union multivalentes.
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9844607B2 (en) * 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
EP2970469B1 (en) 2013-03-11 2018-10-03 Genzyme Corporation Hyperglycosylated binding polypeptides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
CA2903258C (en) * 2013-03-15 2019-11-26 Amgen Inc. Heterodimeric bispecific antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
EP3406633B1 (en) 2013-07-25 2022-03-02 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US9481729B2 (en) * 2013-09-11 2016-11-01 The University Of Hong Kong Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10435453B2 (en) * 2014-02-07 2019-10-08 Mcmaster University Trifunctional T cell-antigen coupler and methods and uses thereof
CA2942769A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
CN104974258B (zh) * 2014-04-01 2019-06-14 三生国健药业（上海）股份有限公司 重组抗hgf/dll4双特异性抗体、其制备方法和应用
US10647777B2 (en) 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
DK3170005T3 (da) * 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
US10064952B2 (en) 2014-10-09 2018-09-04 Genzyme Corporation Glycoengineered antibody drug conjugates
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MA41019A (fr) 2014-11-26 2021-05-05 Xencor Inc Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
MA55043A (fr) 2014-11-26 2021-12-29 Xencor Inc Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
ES2824151T3 (es) * 2014-12-19 2021-05-11 Alkermes Inc Proteínas de fusión Fc monocatenarias
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
CA3138083A1 (en) 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
MA40801A1 (fr) * 2015-01-23 2018-07-31 Sanofi Sa Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3268392A2 (en) 2015-03-13 2018-01-17 CytomX Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
JP7133925B2 (ja) 2015-03-23 2022-09-09 アレクシオン ファーマシューティカルズ インコーポレイテッド ウイルス濾過
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
JP6786526B2 (ja) 2015-06-03 2020-11-18 ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 改変されたｃｃｌ２０ロックド二量体ポリペプチド
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
CN115057936A (zh) * 2015-06-15 2022-09-16 努玛治疗有限公司 异源二聚体多特异性抗体形式
KR102644875B1 (ko) 2015-07-23 2024-03-06 베링거잉겔하임인터내쇼날유한회사 Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도
US20170073399A1 (en) 2015-09-11 2017-03-16 Alexion Pharmaceuticals, Inc. Recombinant glycosylated eculizumab and eculizumab variants
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
WO2017062649A1 (en) 2015-10-07 2017-04-13 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CR20180288A (es) 2015-10-25 2018-09-11 Us Health Proteínas de union triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
CN105294863B (zh) * 2015-11-13 2019-01-22 叶才果 双功能抗体及其用途
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
IL262241B1 (en) 2016-04-13 2024-01-01 Sanofi Sa Trispecific and/or trivalent binding proteins with an arm that has a cross-linking dual variable domain and a traditional FAB antibody arm, the pharmaceutical composition that includes said binding proteins and their uses in the prevention and/or treatment of cancer or inflammatory diseases
FI3443006T3 (fi) 2016-04-13 2023-10-23 Sanofi Sa Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR20190012199A (ko) 2016-05-27 2019-02-08 알렉시온 파마슈티칼스, 인코포레이티드 난치성 전신 중증 근무력증의 치료를 위한 방법
KR102523402B1 (ko) 2016-06-14 2023-04-19 젠코어 인코포레이티드 이중특이적 체크포인트 억제제 항체
CA3026393C (en) 2016-06-22 2023-03-14 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
JP7021127B2 (ja) 2016-06-28 2022-02-16 ゼンコア インコーポレイテッド ソマトスタチン受容体２に結合するヘテロ二量体抗体
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CA3034768A1 (en) 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
EP3529618B1 (en) 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
ES2888904T3 (es) 2016-10-19 2022-01-10 Alexion Pharma Inc Un método de cuantificación de C5a sin unir en una muestra
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
JP7304288B2 (ja) * 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US20200385472A1 (en) * 2017-04-28 2020-12-10 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
US20210188947A1 (en) * 2017-05-10 2021-06-24 The Wistar Institute Of Anatomy And Biology Optimized nucleic acid antibody constructs
AU2018278327B2 (en) 2017-06-01 2023-03-16 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies and methods of use thereof
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
EP4249068A3 (en) 2017-10-10 2023-11-22 Sanofi Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
MX2020006976A (es) * 2018-01-12 2020-10-05 Amgen Inc Anticuerpos del receptor de tipo i del polipeptido activador de la adenilato?ciclasa hipofisaria (pac1) y sus usos.
SG11202006410WA (en) 2018-01-12 2020-08-28 Genzyme Corp Methods for the quantitation of polypeptides
KR20200115568A (ko) 2018-01-26 2020-10-07 젠자임 코포레이션 FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
CN113195523A (zh) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12异源二聚体Fc融合蛋白
AU2019357467A1 (en) 2018-10-09 2021-05-27 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
WO2020106724A1 (en) 2018-11-20 2020-05-28 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
GB2583560A (en) * 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
EP3674316A1 (en) 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
SG11202106525TA (en) 2018-12-24 2021-07-29 Sanofi Sa Multispecific binding proteins with mutant fab domains
BR112021012337A2 (pt) 2018-12-24 2021-09-14 Sanofi Proteínas de ligação multiespecíficas baseadas em pseudofab
CN114173875A (zh) 2019-03-01 2022-03-11 Xencor股份有限公司 结合enpp3和cd3的异二聚抗体
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
AU2020272839A1 (en) * 2019-04-09 2021-12-02 Sanofi Trispecific binding proteins, methods, and uses thereof
MX2021015045A (es) * 2019-06-07 2022-03-17 Amgen Inc Construcciones de unión biespecíficas.
US20210024620A1 (en) 2019-07-25 2021-01-28 Genzyme Corporation Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021026160A1 (en) 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
CR20220054A (es) * 2019-08-15 2022-06-06 Janssen Biotech Inc Materiales y métodos para fragmentos variables de cadena única mejorado
MX2022004881A (es) 2019-10-25 2022-05-16 Sanofi Sa Metodos para analizar el emparejamiento incorrecto de cadenas en proteinas de union multiespecificas.
US20230132241A1 (en) 2020-01-15 2023-04-27 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CN115515643A (zh) 2020-02-28 2022-12-23 建新公司 用于优化的药物缀合的经修饰的结合多肽
CA3173162A1 (en) 2020-03-25 2021-09-30 Eli Lilly And Company Multispecific binding proteins and methods of developing the same
JP2023519699A (ja) * 2020-03-30 2023-05-12 サノフイ スプリットｃｈ２ドメイン
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
AR123548A1 (es) 2020-09-18 2022-12-14 Ichnos Sciences SA Anticuerpos biespecíficos cd47-cd38
KR20230142831A (ko) 2021-01-13 2023-10-11 비스테라, 인크. 인간화된 보체 5a 수용체 1 항체 및 이의 사용 방법
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
EP4322938A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve nk cells cytotoxicity
WO2022219076A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
IL308733A (en) 2021-05-27 2024-01-01 Sanofi Sa Fc variant with increased affinity for Fc receptors and improved thermal stability
WO2023274342A1 (zh) * 2021-06-30 2023-01-05 江苏恒瑞医药股份有限公司 特异性结合baff和il-12/23的抗原结合分子及用途
WO2023081160A1 (en) 2021-11-02 2023-05-11 Visterra, Inc. Fc variants with abolished binding to fcgammar and c1q
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
TW202400660A (zh) 2022-05-06 2024-01-01 瑞士商伊克諾斯科學公司 Cd3/bcma/cd38 三特異性抗體
WO2023222665A1 (en) 2022-05-18 2023-11-23 Sanofi Method, system and apparatus for predicting pk values of antibodies
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2023237690A2 (en) 2022-06-08 2023-12-14 Sanofi Methods for purification of multi-specific antibodies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
RO118524B1 (ro) 1992-11-13 2003-06-30 Idec Pharmaceuticals Corp San Metoda pentru tratarea unei tulburari legata de celulele b
CA2150262C (en) * 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
CN1173878A (zh) * 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230515B1 (hu) 1996-02-09 2016-10-28 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazásai
WO1997038102A1 (en) 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
IL151853A0 (en) * 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
EP2706116A1 (en) * 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2006526408A (ja) 2003-04-22 2006-11-24 アイビーシー、ファーマシューティカルズ 多価タンパク質複合体
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL2158221T3 (pl) * 2007-06-21 2019-02-28 Macrogenics, Inc. Kowalencyjne diaciała i ich zastosowania
CA2696263C (en) * 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
BRPI0918122A8 (pt) * 2008-12-19 2017-01-24 Macrogenics Inc molécula de diabody, diabody, e mólecula dart
WO2010151792A1 (en) 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2686014A1 (en) * 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
MA40801A1 (fr) * 2015-01-23 2018-07-31 Sanofi Sa Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
IL262241B1 (en) * 2016-04-13 2024-01-01 Sanofi Sa Trispecific and/or trivalent binding proteins with an arm that has a cross-linking dual variable domain and a traditional FAB antibody arm, the pharmaceutical composition that includes said binding proteins and their uses in the prevention and/or treatment of cancer or inflammatory diseases
EP4249068A3 (en) * 2017-10-10 2023-11-22 Sanofi Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
AU2019357467A1 (en) * 2018-10-09 2021-05-27 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
US20120251541A1 (en) 2012-10-04
IL228512B (en) 2018-10-31
BR122020011291B1 (pt) 2022-06-14
AU2012236603B2 (en) 2015-06-18
CY1118807T1 (el) 2018-01-10
AR085726A1 (es) 2013-10-23
RS61399B1 (sr) 2021-02-26
CN110256569A (zh) 2019-09-20
SG193916A1 (en) 2013-11-29
BR112013024758B1 (pt) 2022-06-14
JP2022046668A (ja) 2022-03-23
SI2691416T1 (sl) 2016-10-28
BR112013024758A2 (pt) 2018-07-10
IL261674B (en) 2020-06-30
US20180155450A1 (en) 2018-06-07
MY164906A (en) 2018-02-15
JP2020058363A (ja) 2020-04-16
DK3199547T3 (da) 2021-02-08
CN110256568A (zh) 2019-09-20
PT2691416T (pt) 2016-08-26
IL228512A0 (en) 2013-12-31
JP7273135B2 (ja) 2023-05-12
LT2691416T (lt) 2016-09-12
TW201808994A (zh) 2018-03-16
EP3199547B1 (en) 2020-11-18
US20140056895A1 (en) 2014-02-27
JP6877371B2 (ja) 2021-05-26
EP3199547A1 (en) 2017-08-02
IL299392A (en) 2023-02-01
KR20140019420A (ko) 2014-02-14
RU2013147821A (ru) 2015-05-20
CA2831603A1 (en) 2012-10-04
CL2018001827A1 (es) 2018-08-31
TW201722988A (zh) 2017-07-01
JP2014511684A (ja) 2014-05-19
US9181349B2 (en) 2015-11-10
TW201302786A (zh) 2013-01-16
UY33983A (es) 2012-10-31
BR122022004041B1 (pt) 2022-12-06
AR124513A2 (es) 2023-04-05
JP2018087211A (ja) 2018-06-07
EP2691416B1 (en) 2016-05-18
AR124512A2 (es) 2023-04-05
RU2695880C2 (ru) 2019-07-29
RS55014B1 (sr) 2016-11-30
TW202212358A (zh) 2022-04-01
MX338907B (es) 2016-05-05
KR20210042183A (ko) 2021-04-16
AR124511A2 (es) 2023-04-05
CN103562221B (zh) 2019-06-14
US9221917B2 (en) 2015-12-29
EP2691416A1 (en) 2014-02-05
KR102607708B1 (ko) 2023-11-30
DK2691416T3 (en) 2016-09-05
PL2691416T3 (pl) 2016-11-30
KR20230166147A (ko) 2023-12-06
KR101974901B1 (ko) 2019-05-08
EP3805262A1 (en) 2021-04-14
IL261674A (en) 2018-10-31
MA35051B1 (fr) 2014-04-03
PL3199547T3 (pl) 2021-06-14
JP2017038607A (ja) 2017-02-23
US20210189011A1 (en) 2021-06-24
EP3112380A1 (en) 2017-01-04
ZA201307017B (en) 2014-05-28
JP6023172B2 (ja) 2016-11-09
MX2013011176A (es) 2013-11-01
AU2012236603A1 (en) 2013-04-18
HUE028230T2 (en) 2016-12-28
TWI588156B (zh) 2017-06-21
SI3199547T1 (sl) 2021-03-31
IL261673A (en) 2018-10-31
CA2831603C (en) 2020-07-21
TW201940510A (zh) 2019-10-16
JP7003101B2 (ja) 2022-02-04
CO6781527A2 (es) 2013-10-31
JP2023100752A (ja) 2023-07-19
JP6490038B2 (ja) 2019-03-27
TWI803876B (zh) 2023-06-01
US20140011238A1 (en) 2014-01-09
US20160200811A1 (en) 2016-07-14
TWI671315B (zh) 2019-09-11
TW202317615A (zh) 2023-05-01
NZ616174A (en) 2015-10-30
TWI743461B (zh) 2021-10-21
US20130345404A1 (en) 2013-12-26
ES2588306T3 (es) 2016-11-02
WO2012135345A1 (en) 2012-10-04
CN103562221A (zh) 2014-02-05
IL261673B (en) 2020-06-30
TWI622597B (zh) 2018-05-01

Similar Documents

Publication Publication Date Title
HRP20161030T1 (hr) Protutijelu slični vezivni proteini s dvostrukom promjenjivom regijom koji imaju prijelaznu orjentaciju vezivne regije
JP2018087211A5 (hr)
RU2767329C2 (ru) Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
CN106459182B (zh) 串联fab免疫球蛋白及其用途
TWI323734B (en) Dual variable domain immunoglobulin and uses thereof
US9062108B2 (en) Dual specific binding proteins directed against IL-1 and/or IL-17
US20140100359A1 (en) Dual Variable Domain Immunoglobulin and Uses Thereof
CN104804089A (zh) Il-1结合蛋白
KR20080040720A (ko) 이원 가변 도메인 면역글로빈 및 이의 용도
WO2014106015A2 (en) Multivalent binding protein compositions
US20140219913A1 (en) Dual Specific Binding Proteins Having a Receptor Sequence
US20150125397A1 (en) Dual specific binding proteins directed against immune cell receptors and autoantigens
FI3443006T3 (fi) Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja
HRP20210240T1 (hr) Vezujući proteini slični protutijelu s dvostrukom varijabilnom regijom koji imaju unakrsno orjentiranu vezujuću regiju
EP2500357A2 (en) Dual variable domain immunoglobulin and uses thereof
RU2020124746A (ru) Способы количественного определения полипептидов
JPWO2019140320A5 (hr)
WO2023060130A1 (en) Quantitative systems pharmacology in cytokine-based cancer immunotherapy
RU2024102366A (ru) Антитела к cd38 и комбинации с антителами к cd3 и сd28
RU2020115450A (ru) Антитела к cd38 и комбинации с антителами к cd3 и cd28
WO2017085693A1 (en) Reporter gene assay methods for identifying and analyzing multi-specific binding proteins
RU2016149102A (ru) Новый биспецифический формат, подходящий для применения в скрининге с высокой пропускной способностью